PTS Diagnostics

PTS Diagnostics is a long-established, privately-held player in the point-of-care diagnostics market, specializing in portable analyzers for cholesterol and diabetes management. The company leverages a CLIA-waived, battery-powered technology platform that emphasizes accessibility, enabling testing in non-traditional settings from pharmacies to mobile clinics. With a core business model of manufacturing and selling diagnostic devices and consumables, it targets healthcare providers, community health programs, and home users. Its strategy is built on making critical health metrics available rapidly at the point of care to drive timely clinical decisions.

Portable, CLIA-waived, dry-chemistry point-of-care analyzers for lipid panels and HbA1c, featuring battery power, room-temperature storage, and a connectivity suite (PTS Connect) for data transfer.

PTS Diagnostics competes in the point-of-care diagnostics segment against giants like Abbott (e.g., Piccolo Xpress, Afinion), Roche (Cobas b 101, Accu-Chek), and Siemens Healthineers, as well as other focused players like Quest Diagnostics and Trinity Biotech. Its competitive edge lies in the specific portability, ease of use, and battery-operated design of its systems, which are tailored for truly decentralized settings outside traditional labs, a niche where larger players' systems may be less optimized.